CalciMedica Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica Inc. (NASDAQ:CALC) was the target of a large decrease in short interest during the month of July. As of July 15th, there was short interest totaling 960,731 shares, a decrease of 41.8% from the June 30th total of 1,651,945 shares. Based on an average trading volume of 406,881 shares, the days-to-cover ratio is currently 2.4 days. Approximately 10.4% of the company’s stock are sold short.

CalciMedica Price Performance

CALC traded up $0.03 during midday trading on Thursday, hitting $0.77. 89,323 shares of the company’s stock traded hands, compared to its average volume of 1,112,996. The company has a market cap of $12.23 million, a PE ratio of -0.58 and a beta of 0.89. The stock’s fifty day simple moving average is $0.82 and its 200-day simple moving average is $1.14. CalciMedica has a one year low of $0.46 and a one year high of $7.20.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on CALC. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CalciMedica in a report on Tuesday, July 7th. HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a report on Wednesday. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, CalciMedica currently has an average rating of “Hold” and a consensus target price of $10.00.

Insiders Place Their Bets

In related news, Director Fred A. Middleton acquired 248,972 shares of CalciMedica stock in a transaction dated Thursday, June 25th. The stock was acquired at an average price of $0.80 per share, for a total transaction of $199,177.60. Following the transaction, the director owned 1,063,272 shares of the company’s stock, valued at $850,617.60. This represents a 30.57% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 28.25% of the company’s stock.

Institutional Investors Weigh In On CalciMedica

Large investors have recently bought and sold shares of the business. Renaissance Technologies LLC raised its holdings in CalciMedica by 45.0% during the first quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock valued at $69,000 after buying an additional 39,775 shares in the last quarter. 180 Wealth Advisors LLC raised its stake in shares of CalciMedica by 297.2% in the 1st quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock valued at $68,000 after acquiring an additional 94,650 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in CalciMedica by 58.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after purchasing an additional 34,386 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in CalciMedica during the fourth quarter worth approximately $506,000. Finally, PVG Asset Management Corp bought a new position in shares of CalciMedica in the fourth quarter valued at approximately $302,000.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.